Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Care Res (Hoboken)
Главные авторы: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Spondyloarthritis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://ncbi.nlm.nih.gov/pubmed/27696727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23092
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы